AR129314A1 - Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1 - Google Patents

Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1

Info

Publication number
AR129314A1
AR129314A1 ARP230101183A ARP230101183A AR129314A1 AR 129314 A1 AR129314 A1 AR 129314A1 AR P230101183 A ARP230101183 A AR P230101183A AR P230101183 A ARP230101183 A AR P230101183A AR 129314 A1 AR129314 A1 AR 129314A1
Authority
AR
Argentina
Prior art keywords
combination therapy
binding antagonist
atezolizumab
administered
patient
Prior art date
Application number
ARP230101183A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Eng-Wong
Larrocha Pablo Saenz-Lopez
Jeffrey Lau
Nicole Sodir
Joanne Irene Adamkewicz
Danilo Maddalo
Mark Andrew Merchant
Gaurav Pathria
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR129314A1 publication Critical patent/AR129314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ARP230101183A 2022-05-12 2023-05-12 Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1 AR129314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263341361P 2022-05-12 2022-05-12

Publications (1)

Publication Number Publication Date
AR129314A1 true AR129314A1 (es) 2024-08-14

Family

ID=86710772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101183A AR129314A1 (es) 2022-05-12 2023-05-12 Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1

Country Status (10)

Country Link
US (1) US20250312339A1 (enExample)
EP (1) EP4522173A1 (enExample)
JP (1) JP2025516649A (enExample)
KR (1) KR20250012585A (enExample)
CN (1) CN119183377A (enExample)
AR (1) AR129314A1 (enExample)
AU (1) AU2023269154B2 (enExample)
CA (1) CA3248752A1 (enExample)
TW (1) TW202408523A (enExample)
WO (1) WO2023220703A1 (enExample)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
US12281118B2 (en) * 2018-11-07 2025-04-22 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
EP4034539A1 (en) * 2019-09-24 2022-08-03 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same

Also Published As

Publication number Publication date
KR20250012585A (ko) 2025-01-24
EP4522173A1 (en) 2025-03-19
JP2025516649A (ja) 2025-05-30
AU2023269154B2 (en) 2026-05-14
TW202408523A (zh) 2024-03-01
WO2023220703A1 (en) 2023-11-16
AU2023269154A1 (en) 2024-10-10
US20250312339A1 (en) 2025-10-09
CA3248752A1 (en) 2023-11-16
CN119183377A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
ZA202307538B (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
Wachowska et al. 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy
Ascierto et al. What’s new in melanoma? Combination!
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
MX386216B (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
MX2024002822A (es) Composicion farmaceutica y uso de la misma.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
Nasr et al. ST 1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
Nguyen et al. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma
MX2022005664A (es) Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer.
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2025014866A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos
Keller et al. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment
US20180271960A1 (en) Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CR20240385A (es) Terapias combinadas para el tratamiento del cáncer que comprenden un conjugado de farmaco anticuerpo b7-h4
Colquhoun et al. Combination treatment with ionising radiation and gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
MX2025007253A (es) Metodos para tratar los tumores estromales gastrointestinales con ripretinib

Legal Events

Date Code Title Description
FB Suspension of granting procedure